Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03574571 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started2018-06-19
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 88 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

2026-05-13
5 amendments v83-v87
5 re-verifications since 2026-01-08, no change to tracked fields
2026-01-07
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v82
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 738→confirmed 732
Study sitesdetails revised at 72 of 72 sites
2026-01-06
Study Status, Contacts/Locations v81
Study sitesdetails revised at 7 of 72 sites
2025-12-30
Study Status, Contacts/Locations v80
Study sitesdetails revised at 2 of 72 sites
2025-08-15
Study Status, Contacts/Locations v79
Study sites71→72
Show 41 earlier versions
2025-07-01
Study Status, Contacts/Locations v78
Study sites70→71
2025-06-19
Study Status, Contacts/Locations v77
Study sitesdetails revised at 1 of 70 sites
2025-06-10
Study Status, Contacts/Locations v76
Primary completion date2026-06-01→2027-04-01
Completion date2026-06-01→2027-04-01
Study sites71→70
2025-05-21
Study Status, Contacts/Locations v75
Study sitesdetails revised at 1 of 71 sites
2025-04-28
Study Status, Oversight, Contacts/Locations, IPDSharing v74
Study sitesdetails revised at 16 of 71 sites
2025-04-04
Study Status, Oversight, Contacts/Locations, IPDSharing v73
Study sitesdetails revised at 17 of 71 sites
2025-03-14
Study Status, Contacts/Locations v72
Study sitesdetails revised at 1 of 71 sites
2025-01-06
Study Status, Eligibility v71
Eligibility criteria+862 characters
[...] anticancer therapies within 4 weeks prior to randomization. °Note: If this requirement to have a washout of 2 weeks or 5 half-lives prior to randomization causes potential treatment delay due to Radium-223 importation timelines, the PCCTC must be contacted at pcctc@mskcc.org to request approval to randomize the subject prior to the completion of the washout. [...] Received external beam radiotherapy within the 4 weeks prior to randomization. ° Note: If prolonging randomization to complete EBRT washout causes potential treatment delay due to Radium-223 importation timelines, the PCCTC must be contacte [...] [...]
2024-11-20
Study Status, Contacts/Locations v70
Study sites69→71
2024-10-03
Study Status, Contacts/Locations v69
Study sites68→69
2024-09-04
Study Status, Contacts/Locations v68
Study sites67→68
2024-08-15
Study Status, Contacts/Locations v67
Study sites66→67
2024-07-25
Study Status, Contacts/Locations v66
Study sites64→66
2024-05-31
Study Status, Contacts/Locations v65
Study sites63→64
2024-04-24
Study Status, Contacts/Locations v64
Study sites61→63
2024-04-09
Study Status, Contacts/Locations v63
Study sites60→61
2024-03-08
Study Status, Contacts/Locations v62
Study sitescontacts updated at 1 of 60 sites
2024-03-07
Study Status, Contacts/Locations v61
Study sites59→60
2024-01-31
Study Status, Contacts/Locations v60
Study sites58→59
2023-12-08
Study Status v59
Re-verified, no change to tracked fields
2023-11-10
Study Status, Contacts/Locations v58
Study sites57→58
2023-11-07
Study Status, Contacts/Locations v57
Study sites55→57
2023-08-02
Study Status, Contacts/Locations v56
Primary completion date2026-02-01→2026-06-01
Completion date2026-02-01→2026-06-01
Study sites54→55
2023-07-28
Study Status, Contacts/Locations v55
Study sites53→54
2023-04-18
Study Status, Contacts/Locations v54
Study sites53 entries, revised
GUXCancer Research NetworkOmaha / Urology Cancer Center New Mexico CancerOncology Centerand Hematology Houston Methodist HospitalResearch Institute
2023-02-20
Study Status v53
Primary completion date2024-12→2026-02-01
Completion date2024-12→2026-02-01
2023-02-02
Study Status, Contacts/Locations v52
Study sites53 entries, revised
MemoralMemorial Sloan Kettering Basking Ridge MemoralMemorial Sloan Kettering Monmouth
2022-03-30
Study Status, Contacts/Locations v51
Study sites52→53
2021-12-23
Study Status, Contacts/Locations v50
Study sites51→52
2021-12-20
Study Status, Contacts/Locations v49
Study sites50→51
2021-11-09
Study Status, Contacts/Locations v48
Study sites49→50
2021-11-08
Study Status v47
Re-verified, no change to tracked fields
2021-10-26
Study Status v46
Primary completion date2023-06→2024-12
Completion date2023-06→2024-12
2021-09-21
Study Status, Study Description v45
Re-verified, no change to tracked fields
2021-09-16
Study Status, Contacts/Locations v44
Study sites48→49
2021-07-23
Study Status, Contacts/Locations v43
Study sitesdetails revised at 1 of 48 sites
2021-06-01
Study Status, Contacts/Locations v42
Study sitesdetails revised at 1 of 48 sites
2021-05-20
Study Status, Contacts/Locations v41
Study sitesdetails revised at 1 of 48 sites
2021-05-13
Study Status, Contacts/Locations v40
Study sites46→48
2021-05-05
Study Status v39
Re-verified, no change to tracked fields
2021-04-21
Study Status, Study Design v38
Enrollment target693→738
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Trial Details
NCT Number NCT03574571
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Bayer
Conditions Prostate Cancer
Enrollment 732 participants
Start Date 2018-06-19
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-14